MannKind Corporation (NASDAQ:MNKD)
Industry: Biotechnology

Listed 3 Consecutive Market Days. On List as of 01/23/2012 Through 01/26/2012

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Current Quote*
Last: $3.815
Change: 0.000
Book: $Unk
Volume: 1,531,018

As Of: 07/10 16:14 ET
*Quotes delayed by 20min.

Graphs for MNKD


3 Month Graph


6 Month Graph


1 Year Graph